Provider Confidence in Counseling Preconception, Pregnant, and Postpartum Patients Regarding COVID-19 Vaccination

Molly R. Siegel, MD^{1*}; Kaitlyn E. James, PhD, MPH¹; Elana Jaffe, BA, MPH²; Michelle M. L'Heureux, MD, FACP³; Anjali J. Kaimal, MD, MAS¹; Ilona T. Goldfarb, MD¹

¹Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA

² School of Medicine, University of North Carolina at Chapel Hill

³ Massachusetts General Hospital, Boston, MA

*Corresponding Author: Molly R. Siegel, MD, Department of Obstetrics and Gynecology, Massachusetts General Hospital. Email: mrsiegel@partners.org

1 <u>Abstract</u>

Objective: To assess knowledge and confidence in COVID-19 vaccine counseling among
 practitioners who provide care to pregnant persons and to describe factors associated with
 confidence in counseling.

5

Study Design: A web-based anonymous survey was distributed via email to a cross-sectional
convenience sample of OB/GYN, Primary Care, and Internal Medicine faculty at three hospitals
in a single healthcare network in Massachusetts. Individual demographics and institution-specific
variables were included in the survey along with questions assessing both attitudes toward
COVID-19 illness in pregnancy as well as confidence in counseling regarding the use of the
vaccine for pregnant patients.

12

Results: Almost all providers (151, 98.1%) reported already receiving or being scheduled to 13 14 receive a COVID-19 vaccine, and a majority of providers (111, 72.1%) reported that they believe the benefits of the mRNA COVID-19 vaccine in pregnancy outweigh the risks. Forty-one 15 (26.6%) reported feeling very confident in counseling patients who primarily speak English 16 17 about the evidence for mRNA vaccination in pregnancy, and 36 (23%) reported feeling very confident in counseling patients who are not primarily English-speaking. Forty-three providers 18 19 (28.1%) expressed strong confidence in their comfort talking to individuals with vaccine 20 hesitancy based on historic and continued racism and systemic injustices. The sources that 21 survey respondents most commonly used to find information regarding COVID-19 vaccination 22 in pregnancy were the CDC (112, 74.2%), hospital-specific resources (94, 62.3%) and ACOG (82, 54.3%). 23

25	Conclusion: While providers reported high personal uptake of COVID-19 vaccination and felt
26	that the benefits of vaccination outweigh the risks in pregnancy, less than one-third felt very
27	confident in counseling pregnant patients about available evidence for mRNA vaccine safety in
28	pregnancy. Ensuring that providers feel comfortable bridging the gap between their belief that
29	the vaccine is beneficial for pregnant patients and their comfort with holding conversations with
30	patients regarding vaccination is paramount in order to ensure equitable access to vaccines for
31	pregnant patients.
32	
33	
34	<u>Keywords</u>
35	Pregnancy, vaccine hesitancy, COVID-19, prenatal, postpartum, preconception, vaccine
36	counseling
37	

38 Background:

Pregnant people were considered a priority population for COVID-19 vaccination in a majority 39 of states.¹ Their prioritization in vaccine eligibility stems from growing evidence that pregnant 40 individuals are at increased risk of complications from COVID-19 infection, including 41 hospitalization, intensive care unit (ICU) admission, and need for invasive ventilation, and 42 death.² As with other groups at increased risk for complications due to COVID-19, they stand to 43 benefit from vaccination. However, pregnant and lactating persons were not included in early 44 trials of the vaccine, and as such, there are fewer data to inform use in these groups. As a result, 45 patients face potentially challenging decisions surrounding vaccination in pregnancy and 46 lactation. Together with their providers, pregnant individuals must consider the high level of 47 protection afforded by the vaccine together with the limited evidence around vaccine safety in 48 pregnancy, the established increased risk of morbidity and mortality associated with contracting 49 the virus while pregnant, and their individual level of risk due to occupation, underlying medical 50 51 conditions, or other factors.

52

Despite lack of data from randomized controlled trials, the Centers for Disease Control (CDC) 53 54 and the Advisory Committee on Immunization Practices (ACIP), along with the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal Fetal 55 Medicine (SMFM), all support the provision of these vaccines to pregnant and breastfeeding 56 57 individuals. While consultation is not required, these organizations encourage patients to seek 58 counsel from their healthcare providers in deciding whether or not to receive the vaccine and recommend that healthcare providers engage in shared decision making with patients.^{3,4} As 59 pregnant and lactating individuals consider whether they should get the COVID-19 vaccine, it is 60

61	paramount that providers feel knowledgeable and comfortable counseling patients. However,
62	healthcare provider knowledge and confidence surrounding COVID-19 vaccine counseling in
63	pregnancy and lactation has not been assessed.
64	
65	The purpose of this survey study is to assess knowledge and confidence in COVID-19 vaccine
66	counseling among practitioners who provide care to pregnant patients and to describe factors
67	associated with confidence with counseling. It is our goal that understanding these factors will
68	help to identify resources needed to improve healthcare provider confidence and improve
69	counseling around shared decision making for vaccination for pregnant individuals.
70	
71	Methods:
72	Participants
73	The survey participants were drawn from a cross-sectional convenience sample of OB/GYN,
74	Primary Care, and Internal Medicine faculty at three hospitals (one urban academic medical
75	center with 3800 deliveries per year, one suburban community hospital with 4500 deliveries per
76	year, and one rural community hospital with 600 deliveries per year) in a single healthcare
77	network in Massachusetts. Participants were asked via email to participate in an online
78	anonymous survey in February 2021. The survey email was sent to MD, DO, CNM, and NP
79	faculty by their division administrators with two follow-up reminder emails. Consent to
80	participate in the survey was implied by voluntary participation in the anonymous survey.
81	
82	Survey

83	The web-based anonymous survey was designed to accommodate quantitative analysis of
84	questions with nominal, ordinal, and interval level measurement and was reviewed by 3 experts
85	in qualitative research methods and survey design. Individual demographics and institution-
86	specific variables were included in the survey along with questions assessing both attitudes
87	toward COVID-19 illness in pregnancy as well as confidence in counseling regarding the use of
88	the vaccine for preconception, pregnant, and lactating patients.
89	
90	The study and survey instrument were approved by the Partners Healthcare IRB (IRB $\#$
91	2021P000088).
92	
93	Data Analysis
94	Data were analyzed using Stata/IC 16.1. For quantitative variables, descriptive statistics are
95	presented to illustrate the distribution of the respondent demographics and survey responses. To
96	determine predictors of confidence in counseling, multivariable logistic regression models were
97	used. Separate models were generated to determine predictors of confidence and agreement (as
98	defined as responding "very confident" or "strongly agree") in counseling English-speaking and
99	non-English speaking patients about mRNA COVID-19 vaccine safety, and in counseling
100	patients with vaccine hesitancy stemming from historic and ongoing systemic racism and a belief
101	that vaccines in general are harmful. Covariates for the multivariable models were chosen a
102	priori; all models included provider specialty, frequency of being asked advice about COVID-19
103	vaccine, experience managing patients with COVID-19, and a personal belief that the COVID-19
104	vaccine benefits outweighed the risks. Confidence in counseling non-English speaking patients
105	also included whether the respondent spoke more than one language; provider race was

- additionally included in the model for counseling patients with vaccine hesitancy based on
- 107 historic and continued racism. P<0.05 was considered statistically significant.
- 108

109 <u>Results</u>

- 110 *Provider demographics*
- 111 There were 154 providers who responded to the survey. Demographic characteristics are shown
- in Table 1. Almost half of providers worked in obstetrics; approximately 70% of participants
- 113 were medical doctors and a third were advanced practice practitioners. Most respondents
- 114 identified as White/Caucasian and reported English as their primary language, while almost half
- of respondents reported speaking another language in addition to English.
- 116 The majority of participants (140, 91.5%) reported that their institution was offering the COVID-
- 117 19 vaccine to eligible pregnant individuals, and 137 (89.5%) reported that their institution was
- offering the vaccine to postpartum individuals. Most providers (126, 81.8%) reported that since
- 119 December 2020, they had been asked to offer advice surrounding COVID-19 vaccination in
- 120 pregnancy and postpartum to patients at least once per week, and slightly less than half (67,
- 43.5%) % participated in this counseling 2-10 times per week. Most providers (124, 80.5%) had
- 122 cared for patients with COVID-19 in the outpatient setting, though fewer (73, 47.4%) had cared
- 123 for pregnant outpatients with COVID-19. Similarly, while just over half of providers had
- managed patients with COVID-19 in an inpatient setting, fewer (58, 37.7%) reported managing
- 125 pregnant patients with COVID-19 in the inpatient setting.
- 126 Survey respondents had high COVID-19 vaccine utilization for themselves. Almost all providers
- 127 (151, 98.1%) reported already receiving or being scheduled to receive a COVID-19 vaccine.
- 128 Respondents also reported that they frequently recommend other vaccines in pregnancy. Almost

all providers (142, 92.2%) reported that they always recommend the flu vaccine for pregnant
individuals during flu season, and the majority (119, 77.3%) reported that they recommend the
Tdap vaccine for pregnant individuals during every pregnancy.

132 Provider beliefs about risk-benefit ratio

133 Beliefs about the efficacy and safety of mRNA COVID-19 vaccines are shown in Figure 1. A majority of providers (111, 72.1%) reported the opinion that the benefits of the mRNA COVID-134 19 vaccine in pregnancy outweigh the risks. Several (21, 13.6%) were unsure about the risk-135 136 benefit ratio and agreed that additional data and more directive guidance from governing societies would be needed to guide a definitive opinion. A similar number (21, 13.6%) reported 137 that the benefits outweighed the risks only in specific circumstances, including where patients 138 had underlying co-morbidities, increased occupational exposure, lived in congregate housing, or 139 were experiencing incarceration. Only 1 provider (0.6%) stated the belief that the benefits of the 140 COVID-19 vaccine did not outweigh the risks of vaccination in pregnancy, citing unknown fetal 141 safety. The most common rationales supporting the belief that the benefits of COVID-19 142 vaccines outweighed any risk were that pregnant individuals face increased risk of severe disease 143 144 from COVID-19 infection, the likely low theoretical risk of mRNA COVID-19 vaccines in pregnancy, and because vaccine efficacy is likely to be similar between pregnant and non-145 pregnant individuals. The majority of providers (141, 92.2%) agreed that the benefits of 146 147 COVID-19 vaccination during breastfeeding outweighed any risks, with 11 (7.2%) unsure and none in disagreement. Similarly, the majority of providers (133, 86.9%) agreed that the benefits 148 149 of COVID-19 vaccines outweigh the risks for individuals planning pregnancy within three 150 months.

Provider confidence in counseling patients who primarily speak English and those who do not 151 primarily speak English about the vaccine is shown in Figure 2. When asked if that they could 152 153 answer questions about the available evidence for mRNA COVID-19 vaccine safety in pregnant individuals, 41 (26.6%) reported feeling very confident in counseling patients who primarily 154 speak English, and 36 (23%) reported feeling very confident in counseling patients who are not 155 156 primarily English-speaking. There were no differences in confidence in counseling Englishspeaking patients about vaccine safety in pregnancy by provider type, but primary care and 157 internal medicine providers were more likely to state that they feel very confident answering 158 questions from non-English-speaking patients about the available evidence of mRNA COVID-19 159 vaccine safety in pregnant individuals (aOR 4.14, 95% CI 1.25-13.7). 160 161 *Provider comfort with counseling patients with vaccine hesitancy* 162 Provider comfort with counseling patients with vaccine hesitancy is shown in Figure 3. 163 Most providers expressed some confidence in counseling individuals with vaccine hesitancy 164 based on historic and continued racism and systemic injustices (111, 72.5%); however, only 43 165 providers (28.1%) reported feeling strongly confident with this counseling. Similarly, only 50 166 providers described the highest level of comfort counseling individuals with vaccine hesitancy 167

168 grounded in general beliefs that vaccines are harmful. Those who believe the benefits of the

vaccine outweigh the risks were also more likely to strongly agree with the statement that they

- 170 feel comfortable talking to individuals whose vaccine hesitancy was based on historic and
- 171 continued racism and systemic injustice (aOR 4.38, 95% CI 1.47-13.0) and to those whose
- hesitancy is based on beliefs that vaccines in general are harmful (aOR 5.56, 95% CI 1.98-15.6).

173	The sources that survey respondents most commonly used to find information regarding COVID-
174	19 vaccination in pregnancy were the CDC (112 respondents, 74.2%), Hospital-specific
175	resources (94 respondents, 62.3%) and ACOG (82 respondents, 54.3%). When asked to select
176	the tool that would be most useful in helping them feel more confident in counseling pregnant
177	patients regarding COVID-19 vaccination, 32 participants (20.9%) stated "A presentation from
178	an expert in the field of obstetrics and gynecology", 22 participants (14.4%) selected "A decision
179	tool to use with my patients", and 16 participants (10.5%) selected "A handout geared towards
180	patients."

181 <u>Discussion</u>

Vaccination against COVID-19 is considered the cornerstone of pandemic management. CDC 182 recommendations are permissive about COVID-19 vaccine use in pregnancy, though there is no 183 explicit recommendation that pregnant people should receive the vaccine as there is for the 184 general adult population. Guidance from the CDC and ACOG cite provider consultation as 185 186 important (though not required) for decision-making about COVID-19 vaccination in pregnancy. Due to the absence of pregnancy specific vaccine evidence, and a lack of a clear directive to 187 vaccinate all pregnant individuals, provider counseling will play a critical role in COVID-19 188 189 vaccine acceptance among pregnant people.

190

Provider understanding of and feelings towards vaccination have previously been shown to be
key factors in their likelihood of recommending vaccination.⁵⁻⁷ Provider recommendation is also
a significant factor for patient vaccine uptake.⁸⁻¹¹ Despite the CDC's offer for patients to discuss
their decision with a healthcare provider and the pivotal role of healthcare providers in

influencing vaccine uptake, little is known about how ready and confident providers feel toengage in this shared decision-making counseling.

197

In our study, respondents reported a high level of COVID-19 vaccine acceptance for themselves. 198 Vaccinated healthcare providers have previously been shown to be more likely to recommend 199 vaccines to their patients.¹² The high levels of vaccine acceptance in this group suggests that it is 200 a population that would be eager and amenable to counseling patients towards vaccination. 201 Furthermore, most providers believe that the benefits of COVID-19 vaccination in pregnancy 202 outweigh the risks, citing that pregnant individuals face increased risk of severe disease from 203 COVID-19 infection and that there is low theoretical risk of harm from mRNA vaccine in 204 205 pregnancy.

206

However, we identified a discrepancy between provider acceptance of vaccination as beneficial 207 208 for pregnant individuals and their own comfort in engaging in conversations regarding the vaccine in pregnancy. Although 84.1% believed the benefits outweighed the risks in some or all 209 circumstances, fewer expressed some confidence in answering questions about COVID-19 210 211 vaccine safety in pregnancy. Importantly, less than one-third of providers in our survey felt very confident in counseling pregnant patients about available evidence for mRNA vaccine safety in 212 213 pregnancy, despite that nearly half had over 20 years of clinical experience. This disconnect 214 between belief in efficacy and confidence in counseling is of particular concern and may impact 215 the vaccination rates of patients

Overall, providers reported that they most trust information from their institution, the CDC, and 217 ACOG regarding vaccination in pregnancy. Both ACOG and the CDC have developed tools for 218 providers to guide conversations with patients around vaccination.¹³⁻¹⁵ These institutions can 219 continue to provide guidance surrounding vaccine safety and efficacy as well as develop new 220 counseling strategies for providers to improve comfort with counseling. They can engage 221 222 community partners to involve those with vaccine hesitancy in vaccination campaigns and provider interactions. Based on our survey responses, these organizations may consider increased 223 dissemination of information about ongoing presentations from experts in the field of obstetrics 224 and gynecology and decision tools that providers may use with patients to improve confidence 225 with vaccine counseling. 226

227

Although participants in our study reported moderate rates of confidence in counseling patients 228 with vaccine hesitancy, less than one-third of participants strongly agreed that they felt confident 229 230 in counseling patients with vaccine hesitancy based on historic and ongoing racism and systemic injustice. Provider lack of comfort in counseling those with vaccine hesitancy may further 231 232 perpetuate racial inequities that have been highlighted by the pandemic, with disparities in vaccination rates as well as COVID-19 infection, hospitalization, and death rates.^{16,17} As others 233 have pointed out, the concept of "vaccine hesitancy" puts the onus of disparities in vaccination 234 235 rates on the patient rather than the provider and the healthcare systems that perpetuate mistrust and disparity.¹⁸ Our findings suggest a need for broader strategies for educating providers about 236 the impact of systemic racism on both patient uncertainty as well as provider confidence in these 237 encounters to improve confidence in vaccine counseling and ensuring equity in access. One long-238 239 term strategy proposed by Ojikutu et al is to longitudinally partner with and invest in

240 communities of color from the initiation of vaccine research to community education,

community-based organizations, and leadership in order to build trust and provide equitable

242 inclusion in vaccination trials and implementation.¹⁹

243

Strengths of this study include that it represents a cross-sectional and inter-professional sample 244 245 of specialties, practice settings, and provider types to surface the lived experiences of providers engaging in vaccine counseling for a vulnerable population during a pandemic. Limitations 246 include that this study was performed in the early phases of vaccination; as more data 247 surrounding vaccination in pregnancy become available, providers may have shifting comfort 248 with this counseling. Furthermore, participants who opted to complete the survey may have a 249 different level of confidence with this counseling compared to the general provider population. 250 In addition, this sample represents a group of predominantly non-Hispanic White clinicians with 251 high baseline vaccine trust, as nearly all providers received the vaccine themselves, and most 252 253 stated that they always recommend the influenza and Tdap vaccines to pregnant patients. Nearly half spoke a second language, which may increase their confidence in counseling non-English 254 speaking patients. As such, the confidence of this group may overrepresent the confidence of all 255 256 clinicians who engage in vaccine counseling with pregnant patients. Finally, this study was conducted prior to the authorization of the vaccine developed by Janssen, which does not use an 257 mRNA platform. 258

259

260 CONCLUSION

261 As pregnant patients become increasingly eligible for COVID-19 vaccination nationwide,

262 provider-initiated counseling regarding the safety and efficacy of vaccination will necessarily

become a common occurrence in general medicine, primary care, and obstetric care. While the
lack of inclusion of pregnant participants in the initial clinical trials of vaccination makes these
discussions challenging, it also may increase their influence on vaccine uptake. Ensuring that
providers feel comfortable bridging the gap between their belief that the vaccine is beneficial for
pregnant patients and their comfort with holding conversations with patients regarding
vaccination is paramount in order to ensure equitable access to vaccines for pregnant patients.

269

	N=154
Age (mean, SD)	46.2 (11.5)
Race	
Black/African American	6 (3.9%)
White	131 (85.1%)
Asian	11 (7.1%)
Other	3 (1.9%)
Not reported	3 (1.9%)
Ethnicity	
Hispanic/Latinx	5 (3.2%)
Not Hispanic/Latinx	142 (92.2%)
Not reported	7 (4.5%)


270 Table 1: Survey Respondents

Language	
English as primary language	153 (99.4%)
At least one other language	76 (49.4 %)
~ 1	
<u>Gender</u>	
Female	124 (80.5%)
Male	24 (15.6%)
Non-binary	1 (0.6%)
Prefer not to answer	3 (1.9%)
Not reported	2 (1.3%)
Years in healthcare	
< 5 years	7 (4.5%)
5-10 years	37 (24.0%)
10-20 years	38 (24.7%)
>20 years	70 (45.5%)
Not reported	2 (1.3%)
Specialty	
OB-Only	13 (8.4%)
OB/GYN	62 (40.3%)
Primary Care	46 (29.9%)
	40 (29.970)

Internal Medicine	21 (13.6%)
Other	10 (6.5%)
Not reported	2 (1.3%)
Practitioner type	
MD/DO	109 (70.8%)
CNM	26 (16.9%)
NP	19 (12.3%)
Practice Setting	
Private practice, community-hospital	10 (6.5%)
Group practice, community hospital	48 (31.2%)
Private practice, academic hospital	3 (1.9%)
Group practice, academic hospital	86 (55.8%)
Other	7 (4.5%)

274

275 Figure 1: Attitudes towards mRNA COVID-19 Vaccine




278

279 Figure 2: Counseling Confidence in Primarily English Speaking and Primarily Non-English-


- 280 Speaking Patients
- 281

283

282 When Counseling Patients who are Primarily English Speaking





284 When Counseling Patients who are Primarily Non-English Speaking



285

288 Figure 3: Provider Comfort with Counseling Patients with Vaccine Hesitancy





- _/.

297 **References**

- 298 1. Crane MA, Jaffe E, Beigi RH, et al. Prioritization of pregnant individuals in state plans
- for coronavirus disease 2019 vaccination. Am J Obstet Gynecol 2021. DOI:
- 300 10.1016/j.ajog.2021.03.015.
- 2. Yap M, Debenham L, Kew T, et al. Clinical manifestations, prevalence, risk factors,
- 302 outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and
- postpartum: a living systematic review protocol. BMJ Open 2020;10(12):e041868. DOI:
- 304 10.1136/bmjopen-2020-041868.
- 305 3. Advisories ACoP. Vaccinating Pregnant and Lactating Patients Against COVID-19.
- 306 Obstetrics and Gynecology 2020 (<u>https://www.acog.org/clinical/clinical-</u>
- 307 guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients 308 against-covid-
- 309 <u>19#:~:text=ACOG%20recommends%20that%20COVID%2D19,similar%20to%20non%</u>
- 310 <u>2Dlactating%20individuals</u>.).
- 4. SMFM Aa. ACOG and SMFM Joint Statement on WHO Recommendations Regarding
- 312 COVID-19 Vaccines and Pregnant Individuals.
- 313 (https://s3.amazonaws.com/cdn.smfm.org/media/2726/WHO_Response.pdf).
- 5. Dube E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an
- 315 overview. Hum Vaccin Immunother 2013;9(8):1763-73. DOI: 10.4161/hv.24657.
- 316 6. Shavell VI, Moniz MH, Gonik B, Beigi RH. Influenza immunization in pregnancy:
- overcoming patient and health care provider barriers. Am J Obstet Gynecol 2012;207(3
- 318 Suppl):S67-74. DOI: 10.1016/j.ajog.2012.06.077.

- 319 7. Silverman NS, Greif A. Influenza vaccination during pregnancy. Patients' and physicians'
- 320 attitudes. J Reprod Med 2001;46(11):989-94.
- 321 (https://www.ncbi.nlm.nih.gov/pubmed/11762156).
- 322 8. Doherty M, Schmidt-Ott R, Santos JI, et al. Vaccination of special populations:
- Protecting the vulnerable. Vaccine 2016;34(52):6681-6690. DOI:
- 324 10.1016/j.vaccine.2016.11.015.
- 325 9. Wilson RJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing
- 326 vaccination acceptance during pregnancy globally: A literature review. Vaccine
- 327 2015;33(47):6420-9. DOI: 10.1016/j.vaccine.2015.08.046.
- 10. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in
- the United States: How many people would get vaccinated? Vaccine 2020;38(42):6500-
- 330 6507. DOI: 10.1016/j.vaccine.2020.08.043.
- 11. Ellingson MK, Dudley MZ, Limaye RJ, Salmon DA, O'Leary ST, Omer SB. Enhancing
- 332 uptake of influenza maternal vaccine. Expert Rev Vaccines 2019;18(2):191-204. DOI:
- 333 10.1080/14760584.2019.1562907.
- 12. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine
- hesitancy and healthcare providers. Vaccine 2016;34(52):6700-6706. DOI:
- 336 10.1016/j.vaccine.2016.10.042.
- 13. Gynecologists TACoOa. COVID-19 Vaccines and Pregnancy: Conversation Guide for
- 338 Clinicians 2021:<u>https://www.acog.org/covid-19/covid-19-vaccines-and-pregnancy-</u>
- 339 <u>conversation-guide-for-clinicians</u>.

340	14.	Gynecologists TACoOa. COVID-19 Vaccines: Tools for Your Practice and Your Patients
341		2021:https://www.acog.org/covid-19/covid-19-vaccines-tools-for-your-practice-and-
342		your-patients.
343	15.	Control CfD. Answering Patients' Questions About COVID-19 Vaccine and Vaccination.
344		cdc.gov2021: <u>https://www.cdc.gov/vaccines/covid-19/hcp/answering-questions.html</u> .
345	16.	Laurencin CT. Addressing Justified Vaccine Hesitancy in the Black Community. J Racial
346		Ethn Health Disparities 2021. DOI: 10.1007/s40615-021-01025-4.
347	17.	Prevention CfDCa. Risk for COVID-19 Infection, Hospitalization, and Death by
348		Race/Ethnicity.
349	18.	Corbie-Smith G. Vaccine Hesitancy is a Scapegoat for Structural Racism. Jama Health
350		Forum 2021 (https://jamanetwork.com/channels/health-forum/fullarticle/2778073).
351	19.	Ojikutu BO, Stephenson KE, Mayer KH, Emmons KM. Building Trust in COVID-19
352		Vaccines and Beyond Through Authentic Community Investment. Am J Public Health
353		2021;111(3):366-368. DOI: 10.2105/AJPH.2020.306087.
354		
355		